Limitations, agreements, and source contact

Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH · Source last updated 2025-03-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

false

limitations And Caveats

description

Due early termination, only 8 patients were enrolled in the study. The study highlight a high level of toxicity of the experimental treatment.

point Of Contact

email

francesco.zaja@asugi.sanita.fvg.it

organization

SC Ematologia - Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI) - Trieste

phone

+ 39 040 3992015

title

Prof. Francesco Zaja

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice